Hua Medicine New Diabetes Drug Officially Launched to Achieve First Prescription Sales!

Driven by multiple factors such as the continuous growth of diabetic patients in China, the successive entry of new diabetes treatment drugs into the medical insurance catalog, and the enhancement of patients' ability to pay, domestic pharmaceutical companies are stepping up the layout of the field of diabetes drugs, and in this context, domestic diabetes drugs are also constantly achieving new technological breakthroughs
.
Recently, Hua Medicine new drug - glucokinase activator (GKA) huatangning ® (dopagliatin tablets) has achieved prescription sales
in Shanghai.
This means that "blood glucose homeostasis regulation", an innovative treatment for diabetes, has begun to benefit patients
across the country.
It is understood that the new drug is a new mechanism, ectopic allosteric function glucose kinase activator, for use alone, or when metformin hydrochloride glycemic control is poor, combined with metformin hydrochloride, with diet and exercise to improve blood sugar control
in adult patients with type 2 diabetes 。 The new drug is expected to restore the glucokinase function of pancreas-intestinal-liver damage, achieve one-target, multi-point, coordinate sugar control, regulate the secretion of glycemic hormones insulin, GLP-1 and glucagon on a glycemic basis, improve the early phase secretion and disposal index of insulin patients with diabetes, and have the potential to restore blood glucose homeostasis and achieve the remission
of diabetes discontinuation 。 On September 30, the State Medical Products Administration officially approved the new drug application of Huatangning ®, a Class 1 new drug, and was approved for two indications, namely, the treatment of untreated patients with type 2 diabetes mellitus alone, or the combination with metformin alone to treat adult type 2 diabetes when
blood sugar control is not good.
On October 28, the first batch of about 400 pharmacies across the country could be sold
by prescription.
At present, Hua Tangning ® is priced at 420 yuan a box, each box of 28 tablets, 2 tablets a day, which can be taken by a regular patient for 2 weeks
.
Hua Tangning ® is an innovative drug developed by Hua Medicine using the operation model of "combining East and West, joint innovation, sharing and win-win", the industry believes that the product is approved for marketing in China, which means becoming the first first-in-class new drug listed in China, which will provide new treatment options
for patients with type 2 diabetes in China.
At the same time, it has also explored a feasible path
for China to develop the world's first innovative drug.
It is worth mentioning that in order to accelerate the commercialization of new drugs, Hua Medicine is currently making efforts
in many aspects.
It is reported that it has set up a business management team that can reach distributors across the country and built a relatively complete pharmaceutical supply chain system to support the comprehensive listing and business expansion
of products.
At the same time, Hua Medicine has also independently developed a relatively mature drug distributor management system (DMS) to meet the needs of all aspects of drug circulation to use, and assist in future channel innovation digital business
.
In addition, Hua Medicine will work with Bayer to promote the commercialization of Hua Tangning ® in China for the benefit of diabetics and their families
.
At present, the number of diabetes patients in China has reached 140 million, plus nearly 300 million people at risk, and the diabetes drug market has great
potential.
According to Frost & Sullivan data, the scale of China's diabetes drug market has increased year by year in recent years, from 47 billion yuan in 2016 to 65.
4 billion yuan in 2019, with an average increase of 11.
6%; It is expected to reach 167.
5 billion yuan in 2030.

In this context, the industry is highly optimistic about the sales prospects of
Huatang Ning ®.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice
to anyone.